Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 4Phase 1/2 2

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Pancreatic Neoplasms 8Rectal Neoplasms 4Anus Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Adenocarcinoma 3Ovarian Neoplasms 2Klatskin Tumor 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Anal Canal Carcinoma 2Adenocarcinoma Of Esophagus 2Urethral Neoplasms 1Ureteral Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 1Somatostatinoma 1Sinonasal undifferentiated carcinoma 1Paranasal Sinus Neoplasms 1Neoplasm Metastasis 1Metastatic Small Intestinal Adenocarcinoma 1Lung Neoplasms 1Keratosis, Actinic 1HIV Infections 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Clinical Stage I Gastric Cancer AJCC v8 1Clinical Stage 0 Gastric Cancer AJCC v8 1

Interventions

Oxaliplatin 146Fluorouracil 137Capecitabine 121Leucovorin 106Irinotecan 85Radiotherapy 66Bevacizumab 64Cetuximab 46Folfox protocol 27Surgical Procedures, Operative 23Radiation 23Drug Therapy 22Panitumumab 19XELOX 18Chemotherapy, Adjuvant 15Neoadjuvant Therapy 14Radiotherapy, Intensity-Modulated 13Chemoradiotherapy 13Magnetic Resonance Spectroscopy 11regorafenib 10Nivolumab 10Floxuridine 10sintilimab 8raltitrexed 8Specimen Handling 8IFL protocol 8Celecoxib 8Biopsy 8trifluridine tipiracil drug combination 7tislelizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Rectal Neoplasms × dehydroftorafur × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

NCT02921256 2025-12-04

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
363 enrolled 16 charts
Gastrointestinal

Rectal Neoplasms

NCT06780787 2025-06-26

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

City of Hope Medical Center

Phase 2 Recruiting
26 enrolled
Gastrointestinal

Rectal Neoplasms

NCT00321685 2019-03-27

Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
57 enrolled 10 charts
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡